Genprex is a clinical stage gene therapy company focused on developing treatments for cancer and diabetes. Co.'s primary cancer drug candidate, REQORSA Immunogene therapy drug, is being developed to treat non-small cell lung cancer. The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. Co. utilizes its proprietary ONCOPREX® Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. In diabetes, Co. is developing a gene therapy for the treatment of Type 1 and Type 2 diabetes. The GNPX stock yearly return is shown above.
The yearly return on the GNPX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the GNPX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|